Melanoma



A Phase 2/3 Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: Pembrolizumab + Indoximod;   Drug: Pembrolizumab + Placebo;   Drug: Nivolumab + Indoximod;   Drug: Nivolumab + Placebo
Sponsor:   NewLink Genetics Corporation
Not yet recruiting


Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.


Condition:   Melanoma
Interventions:   Drug: Trametinib;   Drug: Dabrafenib;   Drug: INCB039110
Sponsors:   Massachusetts General Hospital;   Incyte Pharmaceuticals;   Sundry
Not yet recruiting


SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients


Conditions:   Melanoma;   Metastatic Melanoma
Interventions:   Radiation: SAbR;   Drug: Ipilimumab;   Drug: Nivolumab
Sponsor:   University of Texas Southwestern Medical Center
Not yet recruiting


LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma


Condition:   Melanoma
Interventions:   Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib
Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company
Recruiting


A Clinical Trial of Patients With Melanoma


Condition:   Melanoma
Interventions:   Drug: Digoxin Combination;   Drug: Dabrafenib;   Drug: Trametinib
Sponsor:   University of Texas Southwestern Medical Center
Recruiting


BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: BGB324+pembrolizumab;   Drug: BGB324+dabrafenib and trametinib;   Drug: pembrolizumab;   Drug: dabrafenib and trametinib
Sponsors:   Haukeland University Hospital;   BerGenBio ASA
Recruiting


A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)


Condition:   Melanoma
Interventions:   Drug: pembrolizumab + epacadostat;   Drug: pembrolizumab + placebo
Sponsors:   Incyte Corporation;   Merck Sharp & Dohme Corp.
Active, not recruiting


Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy


Condition:   Melanoma
Intervention:   Drug: regorafenib
Sponsor:   Yonsei University
Recruiting


Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)


Condition:   Melanoma
Intervention:  
Sponsors:   Daniel Gareau;   Oregon Health and Science University;   University of California, Irvine
Recruiting


Melanoma Perception and Health Literacy in People of Color


Condition:   Melanoma
Interventions:   Behavioral: ABCDEs of Melanoma Skin Cancer;   Behavioral: ABCDEs of Melanoma
Sponsor:   Northwestern University
Completed


Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma


Condition:   Melanoma
Interventions:   Drug: All-Trans Retinoic Acid;   Drug: Ipilimumab
Sponsor:   University of Colorado, Denver
Active, not recruiting


LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma


Condition:   Melanoma
Interventions:   Drug: LGX818;   Drug: MEK162;   Drug: LEE011;   Drug: BGJ398;   Drug: BKM120;   Drug: INC280
Sponsor:   Array BioPharma
Active, not recruiting


Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients


Condition:   Melanoma
Interventions:   Drug: Dabrafenib;   Drug: Trametinib;   Drug: Metformin
Sponsors:   James Graham Brown Cancer Center;   University of Louisville
Recruiting


Treatment of Advanced Melanoma With MK-3475 and Peginterferon


Condition:   Melanoma
Interventions:   Drug: MK-3475;   Drug: Peginterferon alfa-2b
Sponsors:   Hassane M. Zarour, MD;   Merck Sharp & Dohme Corp.;   Melanoma Research Alliance
Active, not recruiting


A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma


Condition:   Melanoma
Intervention:  
Sponsors:   Sanjiv Agarwala, MD;   Merck Sharp & Dohme Corp.
Recruiting


In Vivo Real-time Detection of Circulating Melanoma Cells


Condition:   Melanoma
Intervention:  
Sponsor:   University of Arkansas
Recruiting


Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma


Condition:   Melanoma
Interventions:   Drug: Talimogene laherparepvec;   Drug: Ipilimumab
Sponsor:   Amgen
Active, not recruiting


Interleukin-2 in Metastatic Melanoma


Condition:   Melanoma Metastatic
Intervention:   Drug: Interleukin-2
Sponsor:   Western Regional Medical Center
Terminated


Dacarbazine and Carmustine in Metastatic Melanoma


Condition:   Melanoma Metastatic
Interventions:   Drug: Dacarbazine;   Drug: Carmustine;   Drug: Neulasta
Sponsor:   Western Regional Medical Center
Terminated


A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients


Condition:   Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Metformin
Sponsors:   James Graham Brown Cancer Center;   University of Louisville
Recruiting


Dendritic Cells (DC) Vaccine for Metastatic Melanoma


Condition:   Metastatic Melanoma
Intervention:   Biological: Vaccination
Sponsors:   John Kirkwood;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Terminated


Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma


Condition:   Melanoma
Intervention:   Drug: hu14.18-IL2
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   EMD Serono
Active, not recruiting


Vaccination Plus Ontak in Patients With Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
Sponsors:   University of Chicago;   Eisai Inc.
Active, not recruiting


Characterization of the Melanoma-Specific Immune Response


Condition:   Melanoma
Intervention:  
Sponsor:   University of California, Davis
Recruiting


Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)


Condition:   Melanoma
Interventions:   Drug: Temozolomide;   Drug: Dacarbazine
Sponsors:   Merck Sharp & Dohme Corp.;   European Organisation for Research and Treatment of Cancer - EORTC
Completed

Refine Your Search Advanced Search